Comparison of characteristics based on outcome in 59 patients after transplantation
| . | Total (n = 59) . | Alive (n = 39) . | Dead (n = 20) . | P* . |
|---|---|---|---|---|
| Sex, male/female | 29/30 | 22/17 | 7/13 | NS |
| Age at disease onset, y | 11.8 ± 9.2 | 11.0 ± 9.0 | 13.6 ± 9.5 | NS |
| Clinical category at diagnosis, n | ||||
| CAEBV | 46 | 32 | 14 | NS |
| HLH | 5 | 3 | 2 | NS |
| Severe mosquito bite allergy | 7 | 4 | 3 | NS |
| Hydroa vacciniforme | 1 | 0 | 1 | NS |
| EBV DNA quantity in peripheral blood at diagnosis | ||||
| Mononuclear cells, log copies/μg DNA | 4.5 ± 0.8 | 4.4 ± 0.9 | 4.5 ± 0.89 | NS |
| Plasma, log copies/mL | 3.3 ± 1.6 | 3.3 ± 1.3 | 3.3 ± 2.0 | NS |
| T-cell infection, n | 32 | 23 | 9 | NS |
| NK-cell infection, n | 27 | 16 | 11 | NS |
| Age at HSCT, y | 17.5 ± 9.23 | 15.6 ± 9.1 | 21.2 ± 8.3 | .034 |
| Time from onset to HSCT, mo | 65.0 ± 68.2 | 52.2 ± 54.7 | 90.0 ± 84.8 | .059 |
| Disease status at transplantation, active/inactive | 25/34 | 13/26 | 12/8 | .046 |
| Preceded chemotherapy, n (%) | 42 (71) | 27 (69) | 15 (75) | NS |
| Stem cell source, BM/peripheral blood/cord blood | 35/11/13 | 22/8/9 | 13/3/4 | NS |
| Donor, MRD/MUD/MMRD/MMUD | 18/11/4/26 | 10/9/3/17 | 8/2/1/9 | NS |
| No of mismatched HLA | 0.76 ± 0.9 | 0.76 ± 0.9 | 0.75 ± 0.9 | NS |
| Preconditioning regimen, myeloablative/reduced | 21/38 | 11/28 | 10/10 | .086 |
| . | Total (n = 59) . | Alive (n = 39) . | Dead (n = 20) . | P* . |
|---|---|---|---|---|
| Sex, male/female | 29/30 | 22/17 | 7/13 | NS |
| Age at disease onset, y | 11.8 ± 9.2 | 11.0 ± 9.0 | 13.6 ± 9.5 | NS |
| Clinical category at diagnosis, n | ||||
| CAEBV | 46 | 32 | 14 | NS |
| HLH | 5 | 3 | 2 | NS |
| Severe mosquito bite allergy | 7 | 4 | 3 | NS |
| Hydroa vacciniforme | 1 | 0 | 1 | NS |
| EBV DNA quantity in peripheral blood at diagnosis | ||||
| Mononuclear cells, log copies/μg DNA | 4.5 ± 0.8 | 4.4 ± 0.9 | 4.5 ± 0.89 | NS |
| Plasma, log copies/mL | 3.3 ± 1.6 | 3.3 ± 1.3 | 3.3 ± 2.0 | NS |
| T-cell infection, n | 32 | 23 | 9 | NS |
| NK-cell infection, n | 27 | 16 | 11 | NS |
| Age at HSCT, y | 17.5 ± 9.23 | 15.6 ± 9.1 | 21.2 ± 8.3 | .034 |
| Time from onset to HSCT, mo | 65.0 ± 68.2 | 52.2 ± 54.7 | 90.0 ± 84.8 | .059 |
| Disease status at transplantation, active/inactive | 25/34 | 13/26 | 12/8 | .046 |
| Preceded chemotherapy, n (%) | 42 (71) | 27 (69) | 15 (75) | NS |
| Stem cell source, BM/peripheral blood/cord blood | 35/11/13 | 22/8/9 | 13/3/4 | NS |
| Donor, MRD/MUD/MMRD/MMUD | 18/11/4/26 | 10/9/3/17 | 8/2/1/9 | NS |
| No of mismatched HLA | 0.76 ± 0.9 | 0.76 ± 0.9 | 0.75 ± 0.9 | NS |
| Preconditioning regimen, myeloablative/reduced | 21/38 | 11/28 | 10/10 | .086 |
NS indicates not significant; MRD, matched related donor; MUD, matched unrelated donor; MMRD, mismatched related donor; and MMUD, mismatched unrelated donor.
P < .10 are shown; P < .05 (shown in bold) are statistically significant.